Dylann Cohn-Emery

Associate Editor at MJH Life Sciences

Managing Editor for @TargetedOnc and Peers & Perspectives in Oncology

Featured in: Favicon

mjhlifesciences.com Favicon

cancernetwork.com Favicon

onclive.com Favicon

curetoday.com Favicon

targetedonc.com Favicon

urologytimes.com Favicon

oncnursingnews.com Favicon

thewhitonline.com Favicon

rtforty.com Favicon

newsbreak.com

Articles

JNJ-79635322 Shows Safety/Favorable Responses in R/R Multiple Myeloma

3 weeks ago | cancernetwork.com | Dylann Cohn-Emery

At the recommended phase 2 dose (RP2D), JNJ-79635322 (JNJ-5322), a novel trispecific antibody, demonstrated a manageable safety profile and responses comparable to chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory multiple myeloma, according to initial phase 1 trial (NCT05652335) data presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
Novel Trispecific Antibody Delivers Efficacy and Safety in Myeloma

3 weeks ago | targetedonc.com | Dylann Cohn-Emery

The trispecific antibody JNJ-79635322 (JNJ-5322) showed a manageable safety profile and responses similar to chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory multiple myeloma at the recommended phase 2 dose (RP2D), according to data presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
Navigating the Transformation of AI Cancer Detection and Diagnosis

1 month ago | targetedonc.com | Dylann Cohn-Emery

Read the first half of the interview here. In an interview with Targeted OncologyTM, Stuart J.
AI-Powered Pathology Tools May Boost Precision Oncology

1 month ago | targetedonc.com | Dylann Cohn-Emery

Artificial intelligence (AI) could revolutionize cancer diagnostics by improving accuracy, efficiency, and workflow, while also handling tedious tasks. However, its adoption will depend on the technology and accessibility at individual institutions and practices. “AI will ever replace pathologists [or oncologists], but it's the next new technology that pathologists will employ to help them make better, more accurate diagnoses,” Stuart J. Schnitt, MD, said in an interview with Targeted Oncology.
AlloHeme Enhances Early Relapse Detection in AML and MDS Post-Transplant

2 months ago | targetedonc.com | Dylann Cohn-Emery

AlloHeme, a highly sensitive, noninvasive blood test, demonstrated superior sensitivity compared with traditional methods in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in detecting a risk of relapse posttransplant.1At the 2025 Tandem Meetings, Monzr M. Al Malki, MD, presented the results for AlloHeme,which uses next-generation sequencing (NGS) to monitor chimerism levels for patients after transplant.
Key Trials From ASH 2024 Impact Treatment for Plasma Cell Disorders Going Forward

Feb 20, 2025 | targetedonc.com | Dylann Cohn-Emery

Peers & Perspectives in Oncology editorial board member Marc J. Braunstein, MD, PhD, FACP, discussed the significant advancements in multiple myeloma treatment at the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition, highlighting the efficacy of daratumumab (Darzalex) in combination therapies, chimeric antigen receptor (CAR) T-cell therapy’s high minimal residual disease (MRD)–negativity rates and extended remissions, and what these advancements mean for treatment in 2025.
Ruxolitinib Plus Standard Prophylaxis Lowers GVHD Risk in Myelofibrosis

Feb 17, 2025 | cancernetwork.com | Dylann Cohn-Emery

Data presented at the 2025 Tandem Meeting from a phase 2 study indicate that ruxolitinib (Jakafi), when combined with standard graft-vs-host disease (GVHD) prophylaxis, significantly lowers the risk of developing acute and chronic GVHD without sacrificing survival benefit in patients with myelofibrosis undergoing hematopoietic cell transplantation (HCT).
Ruxolitinib Shows Promise in Preventing GVHD in Myelofibrosis

Feb 14, 2025 | targetedonc.com | Dylann Cohn-Emery

Adding ruxolitinib (Jakafi) to standard graft-vs-host disease (GVHD) prophylaxis reduced incidence of acute and chronic GVHD while maintaining survival rates in patients with myelofibrosis undergoing hematopoietic cell transplantation (HCT), according to data presented at the 2025 Transplantation & Cellular Therapy Meetings.1 The phase 2 prospective study (NCT04384692) conducted at Fred Hutchinson Cancer Center showed grade II to IV acute GVHD occurred in 32% of patients receiving...
Wildfires’ Impact on Patients With Cancer: Lessons in Crisis Response

Feb 11, 2025 | targetedonc.com | Dylann Cohn-Emery

Edward S. Kim, MD, MBA, discussed the impact of recent wildfires on patients with cancer at City of Hope in Duarte, California, in an interview with Peers & Perspectives in Oncology. He highlighted the increased stress and anxiety for patients and staff, with many people evacuated and facing air quality issues. City of Hope implemented protocols, including evacuation plans, patient relocation, and resource distribution.
Telehealth Continues to Show Importance Post COVID-19 in Rare Diseases

Dec 29, 2024 | targetedonc.com | Dylann Cohn-Emery

Peers & Perspectives in Oncology: What is the impact of the current telehealth policies for patients with cancer? PONCE: The impact is enormous. The adoption of it was very quick. Before, in the pre–COVID-19 era, we barely had patients seen through telehealth. And then when COVID-19 hit us, we decided to get creative with how to see our patients.